Summary
Fifty patients with inoperable adenocarcinoma of the lung were randomized in a prospective study to receive either standard doses or high doses of 5-fluorouracil, adriamycin, and mitomycin-C (FAM versus Hi-FAM). The response/stabilization rate was 32% for FAM and 34% for Hi-FAM (P>0.05), and the median survival was 27 weeks for FAM group and 24 weeks for Hi-FAM group (P>0.05). Myelotoxicity was mild in FAM, but moderate to severe in Hi-FAM. It is concluded that Hi-FAM did not yield a higher response rate or median survival compared with FAM, but caused significantly more severe myelotoxicity.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Aisner J, Hansen H (1981) Current status of chemotherapy for non-small cell lung cancer. Cancer Treat Rep 65: 979.
Butler TP, MacDonald JS, Smith FP, Smith LF, Woolley PV, Schein PS (1979) 5-Fluorouracil, adriamycin and mitomycin-C (FAM) chemotherapy for adenocarcinoma of the lung. Cancer 43: 1183.
Carter SK (1982) Chemotherapy of lung cancer. Semin Oncol 9 [Suppl 1]: 40.
Cox JD, Yesner RA (1979) Adenocarcinoma of the lung: recent results from the Veterans Administration Lung Group. Am Rev Respir Dis 120: 1025.
Green RA, Humphrey E, Close H, Patro ME (1969) Alkylating agents in bronchogenic carcinoma. Am J Med 46: 516
Hoffman PC, Bitran JD, Golomb HM (1983) Chemotherapy of metastatic non-small cell bronchogenic carcinoma. Semin Oncol 10: 111
Hyde L, Wolf J, MaCracken S, Yesner R (1973) Natural course of lung cancer. Chest 64: 309
Kung ITM, So KF, Lam TH (1984) Lung cancer in Hong Kong Chinese: Mortality and histological types, 1973–1982. Br J Cancer 50: 381.
Lam WK, So SY, Yu DYC (1983) Clinical features of bronchogenic carcinoma in Hong Kong: Review of 480 patients. Cancer 52: 369
Lee E, Desu M (1972) A computer program for comparing K-samples with right-censored data. Comput Prog Biomed 2: 315.
Rosi DR, Nogeire C, Brown B, Ali M, Ewer M, Samuels M (1981) 5-Fluorouracil, adriamycin, and mitomycin-C (Hi-FAM) chemotherapy for adenocarcinoma of the lung. Cancer 48: 21.
Straus MJ, Selawry OS, Wallach RA (1983) Chemotherapy in lung cancer. In: Straus MJ (ed) lung cancer, clinical diagnosis and treatment. Grune and Stratton, New York, p 261.
Taylor RE, Smith IE, Ford HT, Bryant, BM, Casey AJ, Smyth JF (1980) Failure of intensive combination therap (cyclophosphamide, adriamycin, 5-fluorouracil) to control, adenocarcinoma or large cell anaplastic carcinoma of lung. Cancer Chemother Pharmacol 4: 271.
Valaitis J, Warren S, Gamble D (1981) Increasing incidence of adenocarcinoma of the lung. Cancer 47: 1042.
Vincent RG, Pickren JW, Lane WW, Bross I, Takita H. Houten L, Gutierrez AC, Rzepka T (1977) The changing histopathology of lung cancer — a review of 1682 cases. Cancer 39: 1647.
World Health Organization (1979) WHO handbook for reporting results of cancer treatment. WHO, Geneva (WHO offset publication no. 48).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lam, W.K., So, S.Y., Kung, T.M. et al. 5-fluorouracil, adriamycin, and mitomycin-C (FAM) chemotherapy in advanced adenocarcinoma of the lung: comparison of two dosage schedules. Cancer Chemother. Pharmacol. 19, 269–271 (1987). https://doi.org/10.1007/BF00252986
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00252986